Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
Tuesday, GSK Plc (NYSE:GSK) / Pfizer Inc (NYSE:PFE)-owned ViiV Healthcare said its two-drug HIV regimen Dovato was as effective as Gilead Science Inc's (NASDAQ:GILD) three-drug combo Biktarvy in a head-to-head trial.
周二，葛兰素史克集团（纽约证券交易所代码：GSK）/辉瑞公司（纽约证券交易所代码：PFE）旗下的ViiV Healthcare表示，在一项正面交锋的试验中，其双药HIV方案Dovato与吉利德科学公司（纳斯达克股票代码：GILD）的三种药物组合Biktarvy一样有效。
Japanese pharmaceutical company Shionogi & Company is also a stakeholder in ViiV healthcare.
日本制药公司盐野义公司也是ViiV医疗保健的利益相关者。
ViiV Healthcare released 48-week findings from PASO DOBLE (GeSIDA 11720 study), the largest head-to-head, phase IV randomized clinical trial (RCT) investigating the 2-drug regimen Dovato (dolutegravir/lamivudine [DTG/3TC]) compared to the 3-drug regime Biktarvy (bictegravir/ emtricitabine/tenofovir alafenamide fumarate [BIC/FTC/TAF]) for virologically suppressed HIV-1 patients.
ViiV Healthcare发布了PASO DOBLE（gesIda 11720研究）为期48周的研究结果，这是最大的正面交锋的IV期随机临床试验（RCT），研究了双药方案（多鲁特格拉韦/拉米夫定 [DTG/3TC]）与三种药物方案Biktarvy（bictegravir/恩曲他滨/替诺福韦阿拉芬酰胺）的比较 marate [BIC/FTC/TAF]) 用于病毒学抑制的 HIV-1 患者。
Findings showed that switching to DTG/3TC demonstrated non-inferior efficacy in maintaining viral suppression compared with switching to BIC/FTC/TAF.
研究结果表明，与改用BIC/FTC/TAF相比，改用DTG/3TC在维持病毒抑制方面的效果并不逊色。
In the PASO DOBLE clinical trial, 553 patients switched treatment to either Dovato (n=277) or Biktarvy (n=276).
在PASO DOBLE临床试验中，有553名患者转向了Dovato（n=277）或Biktarvy（n=276）的治疗。
The study found in a key secondary endpoint that weight increased significantly more in participants who switched to BIC/FTC/TAF than in those who switched to DTG/3TC through week 48.
该研究发现，在一个关键的次要终点中，改用BIC/FTC/TAF的参与者体重的增加幅度要比在第48周之前改用DTG/3TC的参与者的体重增加得多。
The proportion of participants with weight gain greater than 5% was significantly higher for Biktarvy, at 29.9%, compared to 20% for Dovato.
Biktarvy的体重增加超过5％的参与者比例明显更高，为29.9％，而多瓦托的这一比例为20％。
Weight change with Dovato was consistent across genders and prior regimens. However, participants switching from abacavir-based regimens experienced a 45% higher rate of over 5% weight gain with Biktarvy compared to Dovato (30.6% vs. 21.1%). When switching from TDF-based regimens, the weight gain rate with Biktarvy was about twice as high as with Dovato (40.7% vs. 19.5%).
Dovato的体重变化在不同性别和以前的治疗方案中都是一致的。但是，与多瓦托相比，改用基于阿巴卡韦的疗法的参与者使用Biktarvy的体重增加率提高了45％（30.6％对21.1％）。从基于TDF的疗法切换时，Biktarvy的体重增加率大约是多瓦托的两倍（40.7％对19.5％）。
In 2023, Dovato generated sales of 1.82 billion pounds, while Biktarvy brought in $11.8 billion.
2023年，多瓦托创造了18.2英镑的销售额，而Biktarvy的销售额为118亿美元。